Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate

April 2014
Oncology Letters;2014, Vol. 7 Issue 4, p1151
Academic Journal
In previously performed animal studies and Phase I-II human trials, Bowman-Birk inhibitor concentrate (BBIC) appeared to be a promising cancer chemopreventive agent. The present study describes the results of two phase I randomized double-blind placebo-controlled trials performed in male subjects to assess the safety and toxicity of the original and new formulations of BBIC administered in a single dose as a suspension in orange juice. The dose of BBIC varied from 800-2,000 chymotrypsin inhibitor (CI) units. The BBI concentration in the serum samples collected from the subjects was analyzed by a dot-blot analysis procedure using the 5G2 monoclonal antibody, which is specific for reduced BBI. A total of 41 subjects were enrolled, 20 in the initial BBIC study and 21 in the second BBIC study. In these human trials, no clinically relevant changes in hematological or biochemical parameters were observed. Overall, BBIC was found to be well-tolerated. For these BBIC single-dose phase I trials, there was no dose-limiting toxicity for BBIC, even at the highest dose evaluated, and there were no apparent differences between the clinical trial results for the two formulations of BBIC. The bioavailability of BBI in the second clinical trial, which used the new BBIC formulation, was approximately 40 to 43% of the BBI bioavailability reached in the first clinical trial, which used the original BBIC formulation. The observed bioavailability difference was attributed to the different BBIC formulations used in these two clinical trials. These trials demonstrated that BBIC is safe when administered in a single dose of up to 2,000 CI units. Therefore, the results from the two trials indicate that a multi-dose trial of BBIC may be safely performed with doses of up to 2,000 CI units per day.


Related Articles

  • Bowman-Birk Protease Inhibitor from Vigna unguiculata Seeds Enhances the Action of Bradykinin-Related Peptides. Álvares, Alice da Cunha M.; Schwartz, Elisabeth Ferroni; Amaral, Nathalia Oda; Trindade, Neidiane Rosa; Rodrigues Pedrino, Gustavo; Silva, Luciano Paulino; de Freitas, Sonia Maria // Molecules;Nov2014, Vol. 19 Issue 11, p17536 

    The hydrolysis of bradykinin (Bk) by different classes of proteases in plasma and tissues leads to a decrease in its half-life. Here, Bk actions on smooth muscle and in vivo cardiovascular assays in association with a protease inhibitor, Black eyed-pea trypsin and chymotrypsin inhibitor (BTCI)...

  • Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells. Souza, Larissa da Costa; Camargo, Ricardo; Demasi, Marilene; Santana, Jaime Martins; Sá, Cézar Martins de; de Freitas, Sonia Maria // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Proteasome inhibitors have been described as an important target for cancer therapy due to their potential to regulate the ubiquitin-proteasome system in the degradation pathway of cellular proteins. Here, we reported the effects of a Bowman-Birk-type protease inhibitor, the Black-eyed pea...

  • Reflections on the Landmark Studies of β-Carotene Supplementation. Duffield-Lillico, Anna J.; Begg, Colin B. // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1729 

    Presents a reflection on the alpha-tocopherol Beta-carotene trial for cancer prevention in the U.S. Reason behind the cancellation of the trial; Ethical considerations for large anti-cancer trials; Assessment on the effects of Beta-carotene on overall mortality.

  • Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Benamouzig, Robert; Uzzan, Bernard; Martin, Antoine; Deyra, Jacques; Little, Julian; Girard, Bernard; Chaussade, Stanislas // Gut;May2010, Vol. 59 Issue 5, p622 

    Background Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas. Cyclooxygenase-2 (COX-2), one of its main target enzymes, is reportedly over-expressed in colorectal adenomas. Aim To assess COX-2 expression, in relation to adenoma recurrence and the protective...

  • Battling Prostate Cancer with 5-Alpha-Reductase Inhibitors: a Pyrrhic Victory? Hoffman, Richard; Roberts, Richard; Barry, Michael // JGIM: Journal of General Internal Medicine;Jul2011, Vol. 26 Issue 7, p798 

    Given the relatively small impact of prostate cancer screening on cancer mortality, experts are now suggesting that chemoprevention with 5-alpha-reductase inhibitors (5-ARI) may be a more effective strategy for cancer control. Two large placebo-controlled randomized trials found that men...

  • Cancer Chemoprevention: Prevention is Better than Cure. Sharma, Rajendra // Journal of Cancer Science & Therapy;2012 Supplement, Vol. 4, preceding p1 

    An introduction is presented in which the editor discusses various reports within the issue on topics including chemoprevention of colorectal and prostate cancer and effectiveness of natural and synthetic chemopreventive agents in cancer inhibition.

  • A Ligand of Peroxisome Proliferator-Activated Receptor..., Retinoids, and Prevention of Preneoplastic Mammary Lesions. Mehta, Rajendra G.; Williamson, Eliabeth // JNCI: Journal of the National Cancer Institute;03/01/2000, Vol. 92 Issue 5, p418 

    Presents a study which investigated the chemoprevention of breast cancer. Materials and methods; Results; Discussion of the results.

  • Purification and Characterization of a Novel Isoform of Mast Cell Tryptase from Rat Tongue1. Okumura, Yuushi; Kudoh, Asako; Takashima, Miwa; Inoue, Masahiro; Sakai, Kentaro; Kido, Hiroshi // Journal of Biochemistry;1996, Vol. 120 Issue 4, p856 

    Rat mast cell tryptase was purified to homogeneity from rat tongue by a series of standard chromatographic procedures. Since the enzyme gave band corresponding to molecular mass of 32–35 kDa on sodium dodecyl sulfate polyacrylamide gel electrophoresis and exhibited a molecular mass of 135...

  • Characterization and Comparison of Protein and Peptide Profiles and their Biological Activities of Improved Common Bean Cultivars ( Phaseolus vulgaris L.) from Mexico and Brazil. Mojica, Luis; Mejía, Elvira // Plant Foods for Human Nutrition;Jun2015, Vol. 70 Issue 2, p105 

    Common bean ( Phaseolus vulgaris L.) is a good source of protein, vitamins, minerals and complex carbohydrates. The objective was to compare protein profile, including anti-nutrient proteins, and potential bioactive peptides of improved common bean cultivars grown in Mexico and Brazil. Bean...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics